Mr. Lichtunger is Chairman & CEO of Starton Therapeutics. Starton is developing new indications for approved medicines in hematological malignancies using a proprietary continuous delivery platform. Mr. Lichtinger is the former President of Pfizer Global Primary Care, and President Pfizer Europe, having held responsibility for 52% of Pfizer Inc. revenues, management of pipeline, and $800 million plus clinical budget. He has experience managing two biotechnology companies as the former President and CEO of Optimer Inc. and Asterias Biotherapeutics. Mr. Lichtinger serves on the Board of Directors for Gemphire Therapeutics and Sanfer de Mexico and sits on the Advisory Board of Zero Gravity. He holds an MBA degree from Wharton School of Business and an engineering degree from the National University of Mexico.
The presentation will focus on the company’s preparation for its STAR-LLD Phase 1 clinical studies and STAR-OLZ Phase 2 clinical studies scheduled to start early 2022.
https://startontherapeutics.app.dealmaker.tech/invitations/starton_506c/view
Speakers: Pedro Lichtinger
Starton is a clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton's strategic platform targets new indications and opportunities to replace the standard of care. Two programs entering clinical development: STAR-LLD in hematologic malignancies (blood cancers, Phase 1) and STAR-OLZ in cancer supportive care (CINV, Phase 2). The experienced Board and management team includes world-renowned scientific leaders in their field leading each program.